We hope everyone is enjoying some sunshine while keeping cool and hydrated. OCRA is keeping busy – planning our Uniting for Hope Ovarian Cancer National Conference; offering support to patients and their loved ones; funding grantees and their quest for better treatments and a cure. Read on to see the latest. Research Advocacy Patient Support … Continued
Targeting a specific oncogene associated with the most common type of ovarian cancer may help increase a patient’s immune response to tumors, according to recent findings from researchers at The Wistar Institute and their colleagues at University of Pennsylvania and The University of Colorado Anschutz Medical Campus. An oncogene is a mutated version of a … Continued
We hope everyone is keeping cool while feeling the warmth from our ovarian cancer community. And we hope to see many of your faces online this September when we host our Ovarian Cancer National Conference! Read below to find out details, along with other important news. Research Advocacy Patient Support Events Ways to Give Did you … Continued
Recent OCRA-funded research has resulted in the creation of a new bioinformatics tool that holds potential for predicting the best treatment combinations for cancer patients. Bioinformatics is a scientific discipline that enables researchers to collect, process and analyze a vast amount of biological and medical data via computers and statistical techniques. In the case of … Continued
May has been officially recognized as National Cancer Research Month. Of course, at OCRA, every month is research month. Below, we highlight breakthroughs in our understanding and treatment of ovarian cancer, thanks to the ongoing work of our grantees. And be sure to keep scrolling down to discover new ways to get involved and get support! Research … Continued
A therapeutic strategy that targets key tumor proteins shows promise for treating the most common subtype of ovarian cancer, according to a recent study led by OCRA grantee Duygu Ozmadenci, PhD, of the University of California, San Diego Moores Cancer Center. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, with approximately 75% of epithelial ovarian cancers … Continued
Audra Moran, President and CEO of OCRA, and Richard Pazdur, MD, Head of the Oncology Center of Excellence at FDA, shared reflections — both personal and professional — about ovarian cancer during a recent discussion. Topics that were covered include the critical role that patients play in research, drug regulation, and the policies that affect the … Continued
There are so many ways to spring into action and knowledge around our shared mission. Read on to learn about promising research findings, how to make your voice heard, ways to receive and generate support, and more! Research Advocacy Patient Support & Programs Events Ways to Give
Though palliative care and hospice care are both used to improve a patient’s quality of life, there are key distinctions between the two — as well as many commonly held misconceptions about how they differ. Dr. Lori Spoozak recently led an in-depth discussion about the two modes of care during an online session held as part of … Continued
With tax season upon us, financial planning is on many people’s minds. While all gifts made by check or credit card are tax-deductible, there are other ways to fund cutting-edge ovarian cancer research that also offer tax benefits. We have new developments that may be of interest: And, of course, there are many other ways … Continued
Update: On 3/11/22, President Biden SIGNED the FY2022 spending bill into law, implementing key ovarian cancer program increases. This represents a major win for the ovarian cancer community, and we applaud all who lent their voices to earn this victory. If you have ever lent your voice on behalf of our shared mission, you — … Continued
Dr. Melanie Weigert, of University of Chicago, is a 2021 recipient of OCRA’s Mentored Investigator Grant. With her project, “Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA,” Dr. Weigert aims to identify biomarkers that can predict how cancer cells will respond to platinum-based treatments, helping guide patients with potentially platinum-resistant cancer toward alternative therapies. Dr. Weigert’s … Continued
Get email updates about research news, action alerts, and ways to join the fight.
